Cargando…
New-onset chronic spontaneous urticaria post–COVID-19 vaccination—South African case series
BACKGROUND: Chronic spontaneous urticaria (CSU) is defined as the spontaneous occurrence of hives, angioedema, or both for more than 6 weeks; several inciting triggers including vaccines have been implicated. Coronavirus disease 2019 (COVID-19) vaccinations have been well tolerated by patients with...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10509972/ https://www.ncbi.nlm.nih.gov/pubmed/37781658 http://dx.doi.org/10.1016/j.jacig.2023.100154 |
_version_ | 1785107868046852096 |
---|---|
author | Craffert, Valmy Day, Cascia Peter, Jonny |
author_facet | Craffert, Valmy Day, Cascia Peter, Jonny |
author_sort | Craffert, Valmy |
collection | PubMed |
description | BACKGROUND: Chronic spontaneous urticaria (CSU) is defined as the spontaneous occurrence of hives, angioedema, or both for more than 6 weeks; several inciting triggers including vaccines have been implicated. Coronavirus disease 2019 (COVID-19) vaccinations have been well tolerated by patients with CSU. However, reports have emerged of CSU triggered by COVID-19 vaccination and this study describes a South African case series. OBJECTIVE: To provide details of the first case series of new-onset CSU post–COVID-19 vaccination in Africa and summarize the global literature of reported cases to date. METHODS: All patients referred to our Urticaria Center of Excellence in Cape Town from the initiation of the COVID-19 vaccine rollout in South Africa (from February 2021 to August 2022) were reviewed to identify patients who developed new-onset CSU within 12 weeks of receiving a COVID-19 vaccine. Medical history, physical examinations, and laboratory investigations were reviewed. RESULTS: More than 20 million adults received COVID-19 vaccinations in South Africa during the study period. Eight patients had new-onset chronic urticaria post–COVID-19 vaccination; 6 of the 8 patients were female, the median age was 41 years (interquartile range [IQR], 38-44), and all had a history of atopy. Only 1 reported COVID-19 infection post vaccination. Chronic urticaria occurred following Pfizer-BioNTech, AstraZeneca, and Janssen Ad26.COV2.S vaccination in 6, 1, and 1 patient, respectively, with a median of 12 days (IQR, 3-38) from vaccination to symptoms onset. The baseline median score for Urticarial Activity Score 7 was 34 (IQR, 29-40), and 5 of the 8 patients (63%) had a total IgE level of more than 43 IU/L. All patients received high-dose antihistamines, with only 3 patients controlled. CONCLUSIONS: New-onset CSU can rarely be triggered by COVID-19 vaccinations, most commonly mRNA vaccines. COVID-19 vaccine–triggered CSU appears to have a phenotype similar to that triggered by other inciting agents and across populations. |
format | Online Article Text |
id | pubmed-10509972 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-105099722023-09-29 New-onset chronic spontaneous urticaria post–COVID-19 vaccination—South African case series Craffert, Valmy Day, Cascia Peter, Jonny J Allergy Clin Immunol Glob Original article BACKGROUND: Chronic spontaneous urticaria (CSU) is defined as the spontaneous occurrence of hives, angioedema, or both for more than 6 weeks; several inciting triggers including vaccines have been implicated. Coronavirus disease 2019 (COVID-19) vaccinations have been well tolerated by patients with CSU. However, reports have emerged of CSU triggered by COVID-19 vaccination and this study describes a South African case series. OBJECTIVE: To provide details of the first case series of new-onset CSU post–COVID-19 vaccination in Africa and summarize the global literature of reported cases to date. METHODS: All patients referred to our Urticaria Center of Excellence in Cape Town from the initiation of the COVID-19 vaccine rollout in South Africa (from February 2021 to August 2022) were reviewed to identify patients who developed new-onset CSU within 12 weeks of receiving a COVID-19 vaccine. Medical history, physical examinations, and laboratory investigations were reviewed. RESULTS: More than 20 million adults received COVID-19 vaccinations in South Africa during the study period. Eight patients had new-onset chronic urticaria post–COVID-19 vaccination; 6 of the 8 patients were female, the median age was 41 years (interquartile range [IQR], 38-44), and all had a history of atopy. Only 1 reported COVID-19 infection post vaccination. Chronic urticaria occurred following Pfizer-BioNTech, AstraZeneca, and Janssen Ad26.COV2.S vaccination in 6, 1, and 1 patient, respectively, with a median of 12 days (IQR, 3-38) from vaccination to symptoms onset. The baseline median score for Urticarial Activity Score 7 was 34 (IQR, 29-40), and 5 of the 8 patients (63%) had a total IgE level of more than 43 IU/L. All patients received high-dose antihistamines, with only 3 patients controlled. CONCLUSIONS: New-onset CSU can rarely be triggered by COVID-19 vaccinations, most commonly mRNA vaccines. COVID-19 vaccine–triggered CSU appears to have a phenotype similar to that triggered by other inciting agents and across populations. Elsevier 2023-07-24 /pmc/articles/PMC10509972/ /pubmed/37781658 http://dx.doi.org/10.1016/j.jacig.2023.100154 Text en © 2023 Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original article Craffert, Valmy Day, Cascia Peter, Jonny New-onset chronic spontaneous urticaria post–COVID-19 vaccination—South African case series |
title | New-onset chronic spontaneous urticaria post–COVID-19 vaccination—South African case series |
title_full | New-onset chronic spontaneous urticaria post–COVID-19 vaccination—South African case series |
title_fullStr | New-onset chronic spontaneous urticaria post–COVID-19 vaccination—South African case series |
title_full_unstemmed | New-onset chronic spontaneous urticaria post–COVID-19 vaccination—South African case series |
title_short | New-onset chronic spontaneous urticaria post–COVID-19 vaccination—South African case series |
title_sort | new-onset chronic spontaneous urticaria post–covid-19 vaccination—south african case series |
topic | Original article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10509972/ https://www.ncbi.nlm.nih.gov/pubmed/37781658 http://dx.doi.org/10.1016/j.jacig.2023.100154 |
work_keys_str_mv | AT craffertvalmy newonsetchronicspontaneousurticariapostcovid19vaccinationsouthafricancaseseries AT daycascia newonsetchronicspontaneousurticariapostcovid19vaccinationsouthafricancaseseries AT peterjonny newonsetchronicspontaneousurticariapostcovid19vaccinationsouthafricancaseseries |